Norway
· Delayed Price · Currency is NOK BerGenBio ASA Statistics
Total Valuation
BerGenBio ASA has a market cap or net worth of NOK 426.05 million. The enterprise value is 225.93 million.
| Market Cap | 426.05M |
| Enterprise Value | 225.93M |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BerGenBio ASA has 39.09 million shares outstanding. The number of shares has increased by 1,817.19% in one year.
| Shares Outstanding | 39.09M |
| Shares Change (YoY) | +1,817.19% |
| Shares Change (QoQ) | +33.41% |
| Owned by Insiders (%) | 3.78% |
| Owned by Institutions (%) | 6.25% |
| Float | 24.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 605.66 |
| PB Ratio | 2.43 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.45 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.05
| Current Ratio | 5.05 |
| Quick Ratio | 4.93 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.55% and return on invested capital (ROIC) is -55.79%.
| Return on Equity (ROE) | -85.55% |
| Return on Assets (ROA) | -44.17% |
| Return on Capital (ROIC) | -55.79% |
| Revenue Per Employee | 34,733 |
| Profits Per Employee | -10.36M |
| Employee Count | 16 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.37% in the last 52 weeks. The beta is 1.62, so BerGenBio ASA's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -3.37% |
| 50-Day Moving Average | 11.92 |
| 200-Day Moving Average | 24.15 |
| Relative Strength Index (RSI) | 46.58 |
| Average Volume (20 Days) | 254,814 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BerGenBio ASA had revenue of NOK 521,000 and -155.41 million in losses. Loss per share was -5.37.
| Revenue | 521,000 |
| Gross Profit | 521,000 |
| Operating Income | -162.16M |
| Pretax Income | -155.41M |
| Net Income | -155.41M |
| EBITDA | -161.94M |
| EBIT | -162.16M |
| Loss Per Share | -5.37 |
Balance Sheet
| Cash & Cash Equivalents | 200.12M |
| Total Debt | n/a |
| Net Cash | 200.12M |
| Net Cash Per Share | 5.12 |
| Equity (Book Value) | 175.26M |
| Book Value Per Share | 4.48 |
| Working Capital | 175.04M |
Cash Flow
| Operating Cash Flow | -175.69M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -31,123.80% |
| Pretax Margin | -29,828.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BerGenBio ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,817.19% |
| Shareholder Yield | -1,817.19% |
| Earnings Yield | -49.25% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 0.01.
| Last Split Date | May 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01 |